[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Yin et al., 2016 - Google Patents

Drugging membrane protein interactions

Yin et al., 2016

View PDF
Document ID
400299032939744517
Author
Yin H
Flynn A
Publication year
Publication venue
Annual review of biomedical engineering

External Links

Snippet

The majority of therapeutics target membrane proteins, accessible on the surface of cells, to alter cellular signaling. Cells use membrane proteins to transduce signals into cells, transport ions and molecules, bind cells to a surface or substrate, and catalyze reactions …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Similar Documents

Publication Publication Date Title
Yin et al. Drugging membrane protein interactions
Stevers et al. A thermodynamic model for multivalency in 14-3-3 protein–protein interactions
Penumutchu et al. Structural insights into calcium-bound S100P and the V domain of the RAGE complex
Pulido et al. Design of a true bivalent ligand with picomolar binding affinity for a G protein-coupled receptor homodimer
Hartmann et al. Sequence-specific solution NMR assignments of the β-barrel insertase BamA to monitor its conformational ensemble at the atomic level
Sijbesma et al. Identification of two secondary ligand binding sites in 14-3-3 proteins using fragment screening
Schiering et al. Dimer formation through domain swapping in the crystal structure of the Grb2-SH2− Ac-pYVNV complex
Tremblay et al. Molecular basis for DPY-30 association to COMPASS-like and NURF complexes
Ahmed et al. Solution nuclear magnetic resonance structure and molecular dynamics simulations of a murine 18.5 kDa myelin basic protein segment (S72–S107) in association with dodecylphosphocholine micelles
Kuznetsov et al. Adaptable lipid matrix promotes protein–protein association in membranes
Watson et al. Discovery, development, and cellular delivery of potent and selective bicyclic peptide inhibitors of Grb7 cancer target
Sun et al. Discovery of an orally active small-molecule tumor necrosis factor-α inhibitor
Olp et al. Metabolically derived lysine acylations and neighboring modifications tune the binding of the BET bromodomains to histone H4
Lindström et al. Native hydrophobic binding interactions at the transition state for association between the TAZ1 domain of CBP and the disordered TAD-STAT2 are not a requirement
Wallin Intrinsically disordered proteins: structural and functional dynamics
Bhate et al. Structure and function of the transmembrane domain of NsaS, an antibiotic sensing histidine kinase in Staphylococcus aureus
Puhl et al. Discovery and characterization of peptide inhibitors for calcium and integrin binding protein 1
Gallagher et al. Consideration of binding kinetics in the design of stapled peptide mimics of the disordered proteins eukaryotic translation initiation factor 4E-binding protein 1 and eukaryotic translation initiation factor 4G
Watson et al. Cyclic peptides incorporating phosphotyrosine mimetics as potent and specific inhibitors of the Grb7 breast cancer target
Huang et al. Activation of E6AP/UBE3A-mediated protein ubiquitination and degradation pathways by a cyclic γ-AA peptide
Kestav et al. Bisubstrate inhibitor approach for targeting mitotic kinase Haspin
Steffek et al. A multifaceted hit-finding approach reveals novel LC3 family ligands
Nubbemeyer et al. Targeting Gαi/s proteins with peptidyl nucleotide exchange modulators
Engelberg et al. Discovery of an H3K36me3-derived peptidomimetic ligand with enhanced affinity for plant homeodomain finger protein 1 (PHF1)
Harms et al. Development of N-terminally modified variants of the CXCR4-antagonistic peptide EPI-X4 for enhanced plasma stability